Navigation Links
Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
Date:11/27/2013

SAN DIEGO, Nov. 27, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the 25th Annual Piper Jaffray Healthcare Conference in New York. The presentation is scheduled for Tuesday, December 3rd  at 11:00 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which the Company is evaluating in the Light Study, a cardiovascular outcomes trial being conducted under a Special Protocol Assessment (SPA) with the FDA. Based on successful results of the Light Study, the Company plans to resubmit the Contrave NDA to the FDA with potential approval by June 2014.The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com. Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Announces Successful Interim Analysis of Contrave Light Study
2. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
3. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
4. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
5. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
6. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
7. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
8. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
9. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
10. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
11. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... in New York, NY on ... James Sapirstein , Chief Executive Officer, ... his live presentation and will be available to participate ...
(Date:7/1/2015)... Pa. , July 1, 2015 Precyse, ... and education, announced today that, as part of its ... an agreement to be acquired by investment firm Pamplona ... private equity investors, Altaris Capital Partners and NewSpring Capital, ... in 1999, has assisted nearly 5,000 healthcare facilities and ...
(Date:7/1/2015)... DUBLIN , June 24, 2015 ... has announced the addition of the "2015 ... to their offering. This new 175-page ... market segments, including diabetes (strips and meters), pregnancy, ... dynamics, size, growth, regulatory requirements, technologies, and competitive ...
Breaking Medicine Technology:ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 32015 Strategies in the Home/Self Testing Market 2
... Instruments Incorporated (TI) (NASDAQ: TXN ) today ... with five new fully integrated AFEs for portable biopotential ... AFEs are the first to offer 16- and 24-bit ... power consumption by more than 94 percent compared to ...
... April 4, 2012  UCB (Euronext Brussels: UCB) and Amgen ... of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical ... "We look forward to working with UCB on ... Harper, M.D., executive vice president of Research and Development ...
Cached Medicine Technology:TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 2TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 3TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 4TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 5UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 2UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 3UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 4UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 5UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 6UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 7
(Date:7/1/2015)... ... , ... For decades, researchers in the genetics field have theorized that the ... changing after development in the womb. Now, researchers from the Icahn School of Medicine ... life – a process which helps to switch genes on and off. This histone ...
(Date:7/1/2015)... NY (PRWEB) , ... July 01, 2015 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – today announced that they will welcome four new members to their industry ...
(Date:7/1/2015)... ... 2015 , ... Ormco Corporation, a leading manufacturer and provider ... for a Lifetime Foundation (S4L) fundraising event held at the 14th Annual Damon ... in its mission to provide free quality orthodontic care to individuals with financial ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... new extraction plant for Linablue®, Spirulina-derived natural blue food coloring. Construction of the ... DIC Group’s U.S. Spirulina* production base, began in May 2014. After commissioning, commercial ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... The Collaborative ... the New York Community Trust. The grant will allow CCF to improve quality of ... practices. , CCF was formed to respond to many changes in New York’s Medicaid ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3
... (Nov. 20, 2010) Columbia University Medical Center will ... researcher who has made important advances in understanding the ... disease. A promising young investigator at Columbia will also ... for disordered lipid metabolism in diabetes. ...
... By Madonna Behen HealthDay Reporter , FRIDAY, ... rising on U.S. college campuses, college officials are trying various ... that targeted off-campus boozing shows some promise, researchers say. ... California cut the level of heavy drinking at private parties ...
... Houston (UH) physicists are using complex computer simulations to ... malfunctioning, may cause Alzheimer,s and cancer. Margaret ... Samiotakis, a physics Ph.D. student, described their findings in ... kinase (PGK) are strongly perturbed by macromolecular crowding," published ...
... construct an online interactive world map which gives stark facts ... and following the birth of their child. Social scientists ... collaboration with the White Ribbon Alliance for Safe Motherhood and ... excess of 160,000 called ,The Atlas of Birth, which also ...
... News) -- People who develop gastroenteritis from E. coli-contaminated ... pressure, kidney problems and heart disease later in life, ... the Walkerton Health Study, which evaluated the long-term health ... (commonly known as stomach flu) in May 2000 after ...
... (HealthDay News) -- Among patients with kidney disease in ... some Hispanics, get sicker faster than whites do, researchers ... chronic kidney disease has been established," study co-author Dr. ... Francisco, said in a news release from the American ...
Cached Medicine News:Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 2Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 3Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 4Health News:Outreach, Enforcement Can Curb College Kids' Drinking: Study 2Health News:Outreach, Enforcement Can Curb College Kids' Drinking: Study 3Health News:UH physicists study behavior of enzyme linked to Alzheimer's, cancer 2Health News:UH physicists study behavior of enzyme linked to Alzheimer's, cancer 3Health News:Online map of maternal health to inform world leaders 2Health News:E. Coli Could Have Long Term Effect on Heart 2Health News:Race Seems to Impact Rate of Kidney Function Decline 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: